Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients

Allon E. Moses, Galia Rahav, Yechezkel Barenholz, Josef Elidan, Badri Azaz, Shmuel Gillis, Masha Brickman, Itzhack Polacheck, Mervyn Shapiro

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Rhinocerebral mucormycosis (zygomycosis) primarily affects diabetic or immunosuppressed patients and typically progresses rapidly; necessitating surgical excision and antifungal therapy with amphotericin B. Large doses of amphotericin B are required for cure, causing significant renal toxicity. Amphotericin B colloidal dispersion (ABCD; Amphocil, Sequus Pharmaceuticals, Menlo Park, CA) is a 1:1 complex of cholesteryl sulfate and amphotericin B, which results in significant reduction of toxicity, especially nephrotoxicity. We describe three patients with life-threatening rhinocerebral mucormycosis treated with ABCD. All patients had high serum creatinine levels due to prior treatment with anaphotericin B; these levels reverted to normal during treatment with ABCD. Two patients with diabetes mellitus were cured after receiving a combination of surgery and ABCD therapy. The third patient, who had myelodysplastic syndrome, had an initial good response, with cure of the fungal infection; however, he eventually died of his primary illness. To the best of our knowledge, this is the first detailed clinical description of the treatment of mucormycosis with ABCD.

Original languageEnglish
Pages (from-to)1430-1433
Number of pages4
JournalClinical Infectious Diseases
Volume26
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Dive into the research topics of 'Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients'. Together they form a unique fingerprint.

Cite this